RNTCP launched as DOTS
The Revised National TB Control Programme rolls out Directly Observed Treatment Short-course nationally, becoming the world's largest TB programme.
India has 27 percent of the world's tuberculosis cases and 36 percent of global TB deaths. PM Modi pledged elimination by 2025. The deadline has passed. Here's what happened and what comes next.
Audio version coming soon
Tuberculosis remains India's deadliest infectious disease. The WHO Global TB Report 2024 estimates around 28 lakh Indian TB cases and over 3.4 lakh TB deaths in a single year, making the country home to roughly 27 percent of all TB and 36 percent of global TB deaths. In 2018 the prime minister pledged that India would eliminate TB by 2025, five years ahead of the SDG target. The deadline has now passed without elimination but with real progress. Case notifications crossed 25 lakh in 2023, the highest ever, and the new BPaL regimen has cut treatment for drug-resistant TB from 18 months to 6 months in pilot districts. Mortality has fallen by close to a quarter since 2015. The unfinished agenda is malnutrition, undiagnosed cases in the private sector and persistent resistance, all of which keep India the world's largest TB country well into the late 2020s.
TB in India is sustained by a stacking of risk factors. Malnutrition is the largest single driver. ICMR estimates that about half of all new TB cases in India are linked to undernutrition, which weakens cell-mediated immunity. Crowded urban housing, poor ventilation and indoor cooking smoke help the bacterium spread between family members. Diabetes triples TB risk and India now has 10 crore diabetics. The private sector handles half of all suspected TB consultations but until 2017 did not have to notify cases, so millions of patients were treated informally with incomplete drug courses, breeding resistance. HIV co-infection, smoking, alcohol and silicosis add further layers. Finally, India's public health workforce in tribal and remote districts is thin, so case finding and contact tracing depend on outreach by ASHA workers and community volunteers. Without addressing all these social drivers, the bacterium will continue to find new hosts even as drugs improve.
Unread picks stay on top. Fresh stories may appear as they are ready โ no extra loading.
India now has 12 million obese children under 19, according to ICMR data. School canteens sell junk food while ultra-processed food advertising targets children.
India collects only 11 million units of blood annually against a need of 15 million. The O-negative shortage is acute, urban blood banks run on single-day reserves, and the rural gap is catastrophic.
India has fewer sports medicine doctors than many US college programs. Cricket and marathons grew fast; specialist care did not, so preventable injuries end careers early.
Biosimilars โ cheaper copies of complex biological drugs โ are worth 50 billion globally. Indian companies are racing to capture that market, threatening to cut the price of cancer and.
Micronutrient gaps hit rich and poor: anaemia stays high, vegetarians often lack B12, and urban adults lack vitamin D. Fortification and better diets can bend the curve if delivery improves.
127 essential medicines are out of stock in government hospitals across 12 states. The shortage hits insulin, antibiotics and cancer drugs. Central procurement failure exposes PM Jan Aushadhi gaps.
Key statistics on TB in India:
Myth 1: TB is a disease of the poor and never strikes the well-off. Fact: TB does follow malnutrition and crowded housing, but India's growing diabetic and smoker population sees TB across income groups. Office workers, students at coaching centres and software professionals in Bengaluru and Pune all show up in private clinics with confirmed TB every year.
Myth 2: Once cough goes away, treatment can be stopped. Fact: This is the single biggest cause of drug resistance. TB drugs must run their full 6-month course for sensitive disease and 6 to 9 months for resistant disease. Stopping early can leave hardier bacteria that come back as MDR-TB, which is far harder and more expensive to cure.
Myth 3: TB is contagious only when there is blood in the cough. Fact: Active pulmonary TB spreads through ordinary coughing and even loud talking, often long before any blood appears. The most infectious phase is in the first weeks before diagnosis, which is why early notification, contact tracing and home ventilation matter so much.
Take Sumitra, a 28-year-old garment worker in Tirupur, diagnosed with pulmonary TB in 2024 after three months of cough. She moved to BPaL after her doctors confirmed the strain was resistant to rifampicin. Six months on, she is sputum-negative but her family carries scars. Her husband took unpaid leave to bring her to follow-up visits, her child stopped attending the local crรจche to avoid exposure, and 32,000 rupees of household savings went into food, travel and additional vitamins. Across India, Ni-kshay Poshan Yojana now sends 500 rupees a month to TB patients during treatment, an important but small support against earnings lost from a disease that lasts months. Stigma is the heaviest invisible cost. Studies from Mumbai and Delhi show many TB patients delay seeking care because they fear losing jobs or being asked to leave rented rooms, and women face higher rejection than men, especially after diagnosis during marriage age.
The bigger meaning of India's TB story is that infectious disease elimination is a stress test for the entire health system. Diagnostics, drug supply, nutrition support, contact tracing, private sector regulation and even housing all have to work together. The long-term consequence of falling short is more drug resistance, more young adults losing earning years and more children orphaned by a curable illness. Lessons from Brazil and Vietnam show that aggressive door-to-door case finding, free drugs, conditional cash transfers and strong private sector engagement can drive TB rates down sharply within a decade. India has the largest TB programme in the world and the most experience. What it needs now is uninterrupted political attention beyond the missed 2025 deadline, more investment in nutrition through Poshan, and an end to private-sector under-reporting. The future shape of India's working-age workforce will partly depend on whether TB is finally treated as a long campaign rather than a slogan.
Chronology
Follow the arc from background to turning points. On mobile, swipe the cards and use the step rail below; on desktop, use the spine to jump.
The Revised National TB Control Programme rolls out Directly Observed Treatment Short-course nationally, becoming the world's largest TB programme.
Government makes drug-resistant TB a notifiable disease after the Hinduja Hospital report of totally drug-resistant TB sparks national alarm.
At the Delhi End TB Summit, Prime Minister Narendra Modi commits India to TB elimination by 2025, five years ahead of the SDG deadline.
Direct benefit transfer of 500 rupees per month begins for TB patients during treatment to support nutrition through cure.
Pandemic lockdowns and reassignment of TB staff to COVID duty cause a 25 percent drop in TB notifications in 2020, a major setback.
The 6-month BPaL and BPaLM regimens for drug-resistant TB are introduced across Indian states, replacing the older 18-month protocol.
India misses the 2025 TB elimination deadline, though incidence has fallen close to 20 percent since 2015 and mortality close to 24 percent.
Step 1/7 events
Understand why it happened, how we got here, and what might come next.